AKBA
Akebia Therapeutics Inc.
$2.79
-$0.03(-1.06%)
63
Overall
--
Value
63
Tech
--
Quality
Market Cap
$750.36M
Volume
1.95M
52W Range
$1.24 - $4.08
Target Price
$7.40
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | $1.5M | $181.2M | $207.7M | $335.0M | $295.3M | $213.6M | $292.5M | $194.6M | $160.2M | ||
| Total Revenue | -- | $1.5M | $181.2M | $207.7M | $335.0M | $295.3M | $213.6M | $292.5M | $194.6M | $160.2M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | $-6.3M | $145.3M | $296.5M | $150.7M | $85.6M | $38.1M | $63.2M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | $1.5M | $181.2M | $200.0M | $189.7M | $-1.8M | $61.0M | $206.9M | $120.5M | $133.0M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-61.5M | $-138.0M | $-257.9M | $-378.1M | $476.0M | $375.8M | $325.5M | $271.8M | $166.7M | $147.5M | ||
| Research & Development | $43.0M | $115.8M | $230.9M | $291.0M | $323.0M | $218.5M | $147.9M | $130.0M | $63.1M | $37.7M | ||
| Research Expense | $43.0M | $115.8M | $230.9M | $291.0M | $323.0M | $218.5M | $147.9M | $130.0M | $63.1M | $37.7M | ||
| Selling, General & Administrative | $18.5M | $22.2M | $27.0M | $87.1M | $149.5M | $153.9M | $174.2M | $174.6M | $100.2M | $106.5M | ||
| Selling & Marketing Expenses | -- | -- | $27.0M | $87.1M | -- | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $18.5M | $22.2M | $-3.2M | $-3.7M | $149.5M | $153.9M | $174.2M | $174.6M | $100.2M | $106.5M | ||
| Salaries & Wages | $-4.7M | $-5.8M | $-12.3M | $-19.0M | -- | -- | -- | -- | $9.3M | $7.8M | ||
| Depreciation & Amortization | $-96.0K | $-295.0K | $-600.0K | $-900.0K | $2.2M | $2.1M | $1.9M | $1.7M | -- | -- | ||
| Depreciation & Amortization | $-96.0K | $-295.0K | $-600.0K | $-900.0K | $2.2M | $2.1M | $1.9M | $1.7M | -- | -- | ||
| Amortization | -- | -- | -- | $-1.5M | $55.1M | $55.1M | $36.0M | $59.0M | $59.0M | $59.0M | ||
| Other Operating Expenses | $-61.5M | $-138.0M | $-257.9M | $67.0K | $-3.5M | $-3.4M | $-3.5M | $-3.2M | $5.7M | $5.0M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-61.5M | $-136.5M | $-76.7M | $-178.2M | $-286.3M | $-376.4M | $-265.3M | $-80.8M | $-46.3M | $-50.5M | ||
| EBITDA | $-60.1M | $-135.0M | $-72.4M | $-170.7M | $-248.5M | $-345.2M | $-228.4M | $-43.3M | $-8.3M | $-27.7M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | $8.9M | $19.9M | $15.7M | $6.0M | -- | ||
| Intinc | $510.0K | $901.0K | $2.8M | $6.2M | $792.0K | $-8.9M | $-19.9M | $-15.7M | $-6.0M | $-18.2M | ||
| Net Non-Operating Interest Income/Expense | $510.0K | $901.0K | $2.8M | $6.2M | $792.0K | $-8.9M | $-19.9M | $-15.7M | $-6.0M | $-18.2M | ||
| Gain on Sale of Securities | -- | -- | -- | -- | -- | -- | -- | $1.1M | $800.0K | -- | ||
| Other Income/Expense | $-287.0K | $188.0K | $-204.0K | $-81.0K | $794.0K | $29.7M | $-2.4M | $-13.7M | $-363.0K | $753.0K | ||
| Other Special Charges | $287.0K | $-188.0K | $204.0K | $81.0K | $-794.0K | $1.9M | $2.4M | $2.2M | $887.0K | $-753.0K | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | -- | $15.9M | $181.0K | $58.0K | ||
| Special Income Charges | -- | -- | -- | -- | -- | -- | $-36.0M | $-15.9M | $-181.0K | $-36.1M | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | $36.0M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-60.7M | $-135.7M | $-73.7M | $-171.9M | $-286.3M | $-377.8M | $-264.5M | $-78.5M | $-51.9M | $-69.4M | ||
| Pre-Tax Income | $-60.7M | $-135.7M | $-73.7M | $-171.9M | $-286.3M | $-383.5M | $-282.8M | $-94.2M | $-51.9M | $-69.4M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | -- | $-28.3M | $-6.6M | -- | -- | -- | -- | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-60.7M | $-135.7M | $-73.7M | $-143.6M | $-279.7M | $-384.8M | $-282.0M | $-94.2M | $-51.9M | $-69.4M | ||
| Net Income (Continuing Operations) | $-60.7M | $-135.7M | $-73.7M | $-143.6M | $-279.7M | $-383.5M | $-282.8M | $-94.2M | $-51.9M | $-69.4M | ||
| Net Income (Discontinued Operations) | $-60.7M | $-135.7M | $-73.7M | $-143.6M | $-279.7M | $-384.8M | $-282.0M | $-94.2M | $-51.9M | $-69.4M | ||
| Net Income (Common Stockholders) | $-60.7M | $-135.7M | $-73.7M | $-143.6M | $-272.6M | $-384.8M | $-282.0M | $-94.2M | $-51.9M | $-69.4M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $662.4M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-61.5M | $-138.0M | $-257.9M | $-384.4M | $621.3M | $671.7M | $478.9M | $357.3M | $204.8M | $174.6M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $26.5M | $37.7M | $43.5M | $58.0M | $118.4M | $138.5M | $165.9M | $182.8M | $187.5M | $210.9M | ||
| Average Shares Outstanding (Diluted) | $26.5M | $37.7M | $49.7M | $58.1M | $118.4M | $138.5M | $165.9M | $182.8M | $187.5M | $210.9M | ||
| Shares Outstanding | $37.9M | $38.8M | $48.3M | $117.1M | $129.9M | $153.5M | $181.2M | $184.2M | $209.4M | $236.2M | ||
| Basic EPS | -- | -- | $0.33 | -- | $-2.36 | $-2.77 | $-1.7 | $-0.51 | $-0.28 | $-0.33 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-2.36 | $-2.77 | $-1.7 | $-0.51 | $-0.28 | $-0.33 | ||
| Diluted EPS | $-2.29 | $-3.6 | $-1.69 | $-2.47 | $-2.36 | $-2.77 | $-1.7 | $-0.51 | $-0.28 | $-0.33 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-1.7 | $-0.51 | $-0.28 | $-0.33 | ||
| OTHER METRICS | ||||||||||||
| Development Expense | -- | -- | -- | -- | -- | -- | -- | -- | $36.0M | -- | ||
| Excise Taxes | -- | -- | -- | -- | -- | -- | -- | $36.0M | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | -- | -- | -- | -- | $-524.0K | -- | ||
| Loss And Loss Adjustment Expected Incurred | -- | -- | -- | -- | -- | $31.5M | $36.0M | -- | -- | -- | ||
| Net Operating Interest Income Expense | $510.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $18.5M | $22.2M | $-3.2M | $-3.7M | $149.5M | $153.9M | $174.2M | $174.6M | $100.2M | $106.5M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | $31.5M | -- | -- | -- | -- | ||
| Other Write Off | -- | -- | -- | -- | -- | -- | -- | $400.0K | $100.0K | $695.0M | ||
| Rent And Landing Fees | $18.5M | $22.2M | $-3.2M | $-3.7M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | -- | -- | $27.0M | $87.1M | -- | -- | -- | -- | -- | -- | ||
| Othspecchg | -- | -- | -- | -- | -- | -- | $36.0M | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | -- | $15.9M | $181.0K | $58.0K | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AKBA | $2.79 | -1.1% | 1.95M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Akebia Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW